№ files_lp_4_process_2_47031
File format: docx
Character count: 3045
File size: 22 KB
Supplementary data describing alterations in mesenchymal cells and stromal components in bone marrow samples from acute myeloid leukemia patients, with a focus on gene expression and functional impacts.
Year:
2021
Region / city:
Not specified
Topic:
Mesenchymal cells in bone marrow of AML patients
Document type:
Research Supplementary Data
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, medical professionals
Effective period:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Author:
Nik Heijmink
Student number:
6706541
Date:
12/08/2024
Type of document:
Writing assignment
Academic program:
Neuroscience and Cognition master program, Experimental and Clinical Neuroscience track
Institution:
University Medical Centre Utrecht
Department:
Department for Developmental Origins of Disease, Division Woman and Baby, Brain Center
City:
Utrecht
Country:
The Netherlands
Daily supervision:
M.J.V. Brandt, PhD
Examiner:
C.H.A. Nijboer, Associate Professor
Secondary examiner:
R.J. Pasterkamp, Full Professor
Main topic:
Hypoxic-ischemic encephalopathy and mesenchymal stem cell-derived extracellular vesicles
Key subjects:
Neuroinflammation, neurogenesis, hypothermia treatment, microglia, subventricular zone, exosomes
Year:
Not specified
Region / City:
Not specified
Topic:
Stem Cells, Regenerative Medicine
Document Type:
Product Description
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Authors:
Cassandra M. Juran; Justina Zvirblyte; Yasaman Sharazi; Angela Kubik; Margareth Cheng-Campbell; Elizabeth Blaber; Eduardo Almeida
Affiliations:
Blue Marble Space Institute of Science at NASA Ames Research Center, Mountain View, CA, USA; Vilnius University, Vilnius, Lithuania; Rensselaer Polytechnic Institute, Troy, NY, USA; NASA Ames Research Center, Moffett Field, CA, USA
Research Field:
Stem cell biology; Bone regeneration; Mechanobiology; Space biology
Key Gene:
CDKN1A (Cdkn1a)
Experimental Models:
Wildtype and Cdkn1a-null mice
Methods:
Single-cell mRNA sequencing; in-vitro mechanical stretch; hindlimb unloading; running wheel and treadmill loading; spaceflight microgravity exposure
Space Mission:
Rodent Research-10 aboard the International Space Station
Duration of Spaceflight:
30 days
Biological Material:
Femur bone marrow; mesenchymal osteoprogenitors; osteoblast lineage cells
Type of Document:
Scientific research article
Institutional Context:
NASA-affiliated and academic biomedical research collaboration
Effective Date:
August 26, 2025
Product Name:
Adipose Mesenchymal Stem Cell Exosomes (ADSC-Exos)
Manufacturer:
YI MIN BIOLOGICAL MEDICINE
Contact Phone:
+86 18506213676
Company Address:
Building 1, Gangtian Industrial Park, No. 99 Gangtian Road, Industrial Park, Suzhou, Jiangsu Province, China
Product Type:
Raw material ingredient
Product Form:
Liquid form; Lyophilized powder form
Core Active Ingredient:
Exosomes secreted by adipose mesenchymal stem cells (≥1×10¹⁰ particles/mL)
Excipients:
Serum-free culture medium; Glycerol (5%-10%)
Non-Containing Components:
No antibiotics; No preservatives; No additional animal-derived materials; No heavy metals (<0.1 ppm)
Exosome Diameter:
30–150 nm (average 80–100 nm)
Marker Proteins:
CD9, CD63, CD81, CD29, CD44, CD73
Sterility:
No bacterial or fungal growth
Endotoxin Content:
<0.5 EU/mL
pH Value (Liquid Form):
6.5–7.5
Purity:
≥90%
Storage Conditions:
2–8°C or -20°C depending on form
Shelf Life:
6–24 months depending on form and temperature
Transportation Requirements:
Professional cold chain; ≤72 hours
Scope of Application:
Scientific research experiments; Cosmetics; Medical devices
Usage Restrictions:
Not for direct injection, oral administration, or direct use as drug or health supplement
Liability Statement:
Manufacturer responsible only under specified storage, transportation, and usage conditions
After-Sales Contact Email:
[email protected]
Revision Policy:
Subject to updates due to technology or regulatory changes
Year:
2026
Region / city:
Global
Subject:
Cell therapy, regenerative medicine
Document type:
Product description
Organization:
[Manufacturer / Supplier Name]
Author:
[Author / Researcher Name, if mentioned]
Target audience:
Researchers, healthcare professionals
Validity period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2021
Region / city:
Tianjin, China
Subject:
Stem Cell Therapy, Neurological Function, Ischemic Stroke, Gut Microbiota
Document type:
Research Article
Organization / Institution:
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome
Author:
Zhao LN, Ma SW, Xiao J, Yang LJ, Xu SX, Zhao L
Target audience:
Researchers, Healthcare professionals, Medical practitioners
Period of validity:
Not specified
Approval date:
December 11, 2021
Date of revisions:
July 6, 2021
Publication date:
December 26, 2021
Year:
2026
Region / City:
Not specified
Topic:
Bone Regeneration, Macrophage Phenotype Switching
Document Type:
Research Article
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Duration:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2010–2025
Region / City:
Italy
Topic:
Molecular profiling of mesenchymal tumors
Document type:
Consensus paper supplement
Institution:
Italian Sarcoma Group
Audience:
Medical researchers, oncologists, pathologists
Methods:
Literature review, PubMed search, article screening
Number of articles reviewed:
2,699
Number of articles included in final analysis:
146
Additional publications considered:
December 31, 2024 – August 31, 2025
Filters applied:
Full text, clinical trials, guidelines, meta-analyses, observational studies, humans, English language
Search strategy:
Next-generation sequencing, genomic profiling, liquid biopsy, RNAseq, fusion panel, methylation
Reference list selection:
Most relevant articles according to journal guidelines
Systematic review type:
Consensus-based literature review
Screening process:
Title screening, abstract evaluation, full-text evaluation
Year:
2024
Region / City:
Australia
Theme:
Pharmaceutical benefits, Chronic myeloid leukaemia (CML) treatment
Document type:
Research analysis
Organization / Institution:
Drug Utilisation Sub-Committee (DUSC)
Author:
Drug Utilisation Sub-Committee (DUSC)
Target audience:
Healthcare professionals, policymakers, pharmaceutical industry
Period of validity:
From March 2022 onward
Approval date:
October 2024
Date of changes:
March 2022
Year:
2021
Region / city:
Australia
Topic:
Pharmaceutical Drug Submission
Document type:
Resubmission Request
Organization / institution:
PBAC
Author:
AbbVie Pty Ltd.
Target audience:
Healthcare professionals, PBAC
Validity period:
Not specified
Approval date:
2021
Date of amendments:
Not specified
Year:
2022
Region / City:
Australia
Topic:
Oncology / Hematology
Document Type:
Submission Report
Organ / Institution:
Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Celgene Pty Limited
Target Audience:
Healthcare professionals, regulatory authorities
Validity Period:
Ongoing
Approval Date:
8 April 2022
Amendment Date:
Not specified
Authors:
Myung Sup Kim; Hyeokgu Kang; Jung-Hwan Baek; Moon-Gyu Cho; EunJoo Chung; Seok-Jun Kim; Joon-Yong Chung; Kyung-Hee Chun
Corresponding author:
Kyung-Hee Chun
Affiliation:
Department of Biochemistry & Molecular Biology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea
Additional institutions:
Institute of Genetic Science, Yonsei University College of Medicine; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Chosun University, Gwangju, Republic of Korea
Region / Country:
Republic of Korea; United States of America
Type of document:
Supplementary figures and experimental descriptions for a biomedical research article
Field of study:
Cancer immunology; molecular and cellular biology
Key topics:
Notch signaling; HES1; macrophage differentiation; tumor-associated macrophages; CD8+ T cells; MMTV-PyMT mouse model; TC-1 tumor model
Experimental models:
Murine spontaneous and subcutaneous tumor models; MMTV-PyMT mice; LysM-Hes1 conditional knockout mice; BMDMs; THP-1 cells
Methods:
Flow cytometry; qRT-PCR; RNA sequencing; Western blotting; luciferase reporter assay; immunohistochemistry; antibody-mediated depletion
Genes and proteins analyzed:
HES1; NICD; INOS; STAT6; Arg1; RBPJ; IFNγ; CD4; CD8
Supplementary material:
Figures S1–S10
Contact information:
Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea; Phone: 82-2-2228-1699; E-mail: [email protected]
Year:
Not specified
Disease:
Acute Myeloid Leukemia (AML)
Genetic Focus:
FLT3 mutations (TKD, ITD, ITD-TKD)
Treatment Groups:
FLT3 inhibitors (FLT3i) vs Conventional Chemotherapy (CT)
Endpoints:
Overall Survival (OS); Event-Free Survival (EFS); Time to Transplant
Study Period:
Before and after 2018 approval of FLT3 inhibitors
Statistical Methods:
Logistic regression; Propensity score weighting; Inverse probability weighting; Cox proportional hazard models; Mediation analysis; Sensitivity analysis
Confounders Considered:
Sex; Age; AML type; FLT3 mutation type; White-blood cell count; Platelet count; ELN risk classification; Ongoing comorbidities
Risk Classification System:
European LeukemiaNet (ELN)
Supplementary Material:
Table S1 (subgroup analyses with inverse probability weighting); Table S2 (baseline characteristic survival analyses)
Key Measures:
Hazard Ratios (HR); 95% Confidence Intervals (CI); p-values
Regulatory Milestone Referenced:
Clinical approval of FLT3 inhibitors in 2018
Year:
2017
Region / City:
N/A
Topic:
Hematologic Toxicities, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Document Type:
Meta-analysis
Organization:
N/A
Author:
N/A
Target Audience:
Researchers, Healthcare Professionals
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
2/2018
Year:
2019
Region / City:
United Kingdom
Topic:
Cancer, Hematology
Document Type:
Response to Consultation
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
National Institute for Health and Care Excellence (NICE)
Target Audience:
Healthcare professionals, policy makers
Effective Period:
Not specified
Approval Date:
Not specified
Amendment Date:
June 2019
Year:
2023
Region / city:
Pittsburgh, PA, U.S.A.
Topic:
Hematology, Oncology, Dermatology
Document type:
Case Report
Institution:
Allegheny General Hospital
Author:
Muhammad Ali Butt, Sameen Aamer, Anastasios Kapetanos
Target audience:
Healthcare professionals, researchers in hematology and oncology
Date of approval:
Not specified
Date of changes:
Not specified
Keywords:
Henoch-Schonlein Purpura, acute myeloid leukemia, cutaneous presentation of acute myeloid leukemia
Abstract:
This document reports an unusual case of Henoch-Schonlein Purpura (HSP) as the presenting symptom of Acute Myeloid Leukemia (AML).
Contextual description:
A case report of a patient who presented with a rash consistent with Henoch-Schonlein Purpura, later diagnosed with Acute Myeloid Leukemia.
Year:
N/A
Region / City:
N/A
Subject:
Immunology
Document Type:
Research Supplement
Organization / Institution:
R&D Systems, ThermoFisher, Biolegend, Invitrogen, eBioscience
Author:
N/A
Target Audience:
Researchers in Immunology
Effective Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2024
Type of Document:
Clinical protocol
Scope:
Myeloid and mixed/ambiguous lineage neoplasms
Applicable Sites:
Bone marrow, blood, cutaneous, extranodal/mucosal, other anatomic sites
Authors:
Robert W. Allan, L. Jeffrey Medeiros, Robert Seifert, Claudio A. Mosse, Samer Z. Al-Quran, Joseph D. Khoury
Issuing Organization:
CAP Cancer and CAP Pathology Electronic Reporting Committees
Version:
1.1.0.0
Protocol Posting Date:
June 2024
Target Audience:
Pathologists and clinicians involved in hematologic malignancy diagnosis
Changes Summary:
Typographical correction in SPECIAL STUDIES section from "interim" to "internal"
Year:
2023
Region / City:
Not specified
Topic:
Leukemia Cutis, Chronic Myeloid Leukemia
Document Type:
Case Report
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, researchers
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified